CFTR and cystic fibrosis: Meanwhile the triple combination of the potentiator ivacaftor (IVA) and the two correctors elexacaftor (ELX) and tezacaftor (TEZ) has become available for the treatment of the more than 90% of people with CF (pwCF) who harbour at least one CFTR allele that is responsive to this medication (Middleton et al., 2019).